References
- Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2003; 158: 765–74
- McGorry PD. Recommended haloperidol and risperidone doses in first-episode psychosis. J Clin Psychiatry 1999; 60: 794–5
- Montes JM, Ciudad A, Gascon J, et al. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 667–74
- Huguelet P, Girardet F. A Swiss retrospective naturalistic outcome study comparing risperidone and olanzapine in the treatment of schizophrenic insubjects. Schweiz Arch Neurol Psychiatr 2002; 153: 282–8
- Lambert, M, Conus, P, Schimmelmann, B, et al. Comparison of Olanzapine and Risperidone in 367 first-episode patients with non-affective or affective psychosis. Pharmacopsychiatry, in press.
- Godleski LS, Goldsmith LJ, Vieweg WV, et al. Switching from depot antipsychotic drugs to olanzapine in subjects with chronic schizophrenia. J Clin Psychiatry 2003; 64: 119–22
- Dossenbach MRK, Kratky P, Schneidman M, et al. Evidence for the effectiveness of olanzapine among subjects non-responsive and/or intolerant to risperidone. J Clin Psychiatry 2001; 62(Suppl 2)28–34
- Lambert M, Conus P, Lambert T, McGorry PD. Pharmacotherapy of first-episode schizophrenia. Expert Opin Pharmacother 2003; 4: 717–51
- McGorry PD, Killackey E, Lambert M, Elkins K, Lambert T. Summary Australian and New Zealand Clinical Practice Guidelines for the treatment of schizophrenia. Australasian Psychiatry 2003; 11: 1–13
- American Psychiatric Association. Diagnostic Criteria from DSM-IV. American Psychiatric Press, Washington, DC 1994
- Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. National Institute of Mental Health, Rockville, 1976.
- Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated subjects. Acta Psychiatr Scand 1987; 334: 1–100
- Kane, JM, Leucht, S, Carpenter, D. Expert consensus guidelines for optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(Suppl 12)
- Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544–9
- Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in subjects with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004; 185: 18–24
- Pantelis C, Lambert TJ. Managing patients with “treatment-resistant” schizophrenia. Med J Aust 2003; 178: 62–6
- Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; 2: CD005237
- Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 668 patients with first-episode psychosis. Acta Psychiatrica Scand 2005; 112: 141–8
- Schimmelmann, BG, Conus, P, Edwards, J, McGorry, PD, Lambert, M. Diagnostic stability 18 months after a first diagnosis of psychosis. J Clin Psychiatry, in press.